Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs by Boel, Eline et al.
Contents lists available at ScienceDirect
European Journal of Pharmaceutics and Biopharmaceutics
journal homepage: www.elsevier.com/locate/ejpb
Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in
the formulation of amorphous solid dispersions of poorly soluble drugs
Eline Boela, Annelies Smeetsa, Maarten Vergaelenb, Victor R. De la Rosab, Richard Hoogenboomb,
Guy Van den Mootera,⁎
a KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, 3000 Leuven, Belgium
b Supramolecular Chemistry Group, Centre of Macromolecular Chemistry (CMaC), Department Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-
S4, 9000 Gent, Belgium
A R T I C L E I N F O
Keywords:
Amorphous solid dispersion
Poly(2-ethyl-2-oxazoline)
Spray drying
Hot melt extrusion
Cryo-milling
A B S T R A C T
Despite the fact that solid dispersions are gaining momentum, the number of polymers that have been used as a
carrier during the past 50 years is rather limited. Recently, the poly(2-alkyl-2-oxazoline) (PAOx) polymer class
profiled itself as a versatile platform for a wide variety of applications in drug delivery, including their use as
amorphous solid dispersion (ASD) carrier. The aim of this study was to investigate the potential of poly(2-ethyl-
2-oxazoline) (PEtOx) by applying a benchmark approach with well-known, commercially available carriers (i.e.
polyvinylpyrrolidone (PVP) K30, poly(vinylpyrrolidone-co-vinyl acetate) (PVP-VA) 64 and hydro-
xypropylmethylcellulose (HPMC)). For this purpose, itraconazole (ITC) and fenofibrate (FFB) were selected as
poorly water-soluble model drugs. The four polymers were compared by establishing their supersaturation
maintaining potential and by investigating their capability as carrier for ASDs with high drug loadings. Spray
drying, as well as hot melt extrusion and cryo-milling were implemented as ASD manufacturing technologies for
comparative evaluation. For each manufacturing technique, the formulations with the highest possible drug
loadings were tested with respect to in vitro drug release kinetics. This study indicates that PEtOx is able to
maintain supersaturation of the drugs to a similar extent as the commercially available polymers and that ASDs
with comparable drug loadings can be manufactured. The results of the in vitro dissolution tests reveal that high
drug release can be obtained for PEtOx formulations. Overall, proof-of-concept is provided for the potential of
PEtOx for drug formulation purposes.
1. Introduction
Since the early nineties, drug selection procedures have experienced
dramatic changes, driven by the advent of rational drug design strate-
gies like high throughput screening and combinatorial chemistry. These
procedures often lead to new drug candidates that tend to have a high
affinity and selectivity for their biological targets but on the other hand
imply discovery of drug candidates with unfavourable properties, in
particular low aqueous solubility and consequently low bioavailability
after oral administration [1,2]. Most of these drugs are therefore
classified as BCS (Biopharmaceutics Classification System) class II
compounds, which are characterized by low solubility and high per-
meability and, hence, their dissolution rate and solubility are the rate
limiting steps in oral absorption. The evolution towards these new drug
candidates with low aqueous solubility is evidenced by the shift in the
share of BCS class II drugs from 33% of marketed drugs towards 54% of
new chemical entities [3]. This means that currently more than 50% of
newly developed drug compounds need an enabling formulation
strategy, emphasizing the increasing importance of studying innovative
drug formulations. Throughout the years, many strategies have been
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developed to formulate BCS class II compounds with a view to over-
come poor solubility, including particle size reduction to the nanometer
range, formation of water soluble complexes (e.g. cyclodextrin com-
plexes), self-emulsifying drug delivery systems, ordered mesoporous
silica, co-crystals, co-solvency, salt formation and amorphous solid
dispersions (ASDs) [2]. Among them, ASDs offer great potential to
tackle low oral bioavailability issues [2,4,5]. Since no lattice energy
must be overcome in amorphous materials, the rate and extent of dis-
solution is improved compared to crystalline materials. However, these
amorphous materials also possess a higher Gibbs energy and from a
thermodynamic point of view, materials always try to lower their Gibbs
energy in order to aspire an increase in total entropy [6]. Amorphous
materials are therefore thermodynamically unstable and tend to un-
dergo structural relaxation, nucleation and crystallization. Due to this
thermodynamic instability, amorphous drugs can hardly ever be mar-
keted as such [7]. This problem is addressed by molecularly dispersing
the poorly soluble drug within an inert polymer matrix (“carrier”) in
the solid state to create a so-called ASD [4]. The aforementioned
thermodynamic instability of the amorphous drug can consequently be
avoided due to anti-plasticizing effects of the carrier by increasing the
glass transition temperature (Tg) and the creation of a physical barrier
related to the higher viscosity of the carrier. Reduction in the chemical
potential of the drug and most notably inter-molecular interactions
with the carrier such as hydrogen bonds also play a key role in the
physical stability of ASDs. Moreover, the carrier must be able to install
and maintain supersaturation of the drug in the gastrointestinal tract in
order to reach an adequate driving force for absorption [8,9].
ASDs can be prepared in a variety of ways, namely by rapid cooling
of a melt, precipitation of a drug-carrier solution or by direct solid
conversion methods. These can be classified as heat-based methods,
solvent-based methods and mechanochemical-based methods, respec-
tively [10]. Because different preparation methods entail altered final
product properties, an adequate rational selection of a manufacturing
technology is indispensable [7]. Heat-based methods apply the prin-
ciple of rapid cooling of a melt as amorphization procedure and en-
compass spray congealing, melt granulation and hot-melt extrusion
(HME). Such heat-based methods are only reliable for thermostable
drugs but are of utmost importance regarding upscaling and continuous
manufacturing purposes [7]. Solvent-based methods use the inter-
mediate step of a solution to convert the crystalline material into the
amorphous state. Examples of these methods are film casting, bead
coating, co-precipitation, freeze drying, electrospraying and spray
drying [4]. A huge benefit over the heat-based methods is that more
thermolabile drugs can be processed. Nonetheless, one must be aware
of the drawbacks associated with the use of solvents with respect to
potential toxicological and environmental issues. Mechanochemical
activation (e.g. cryo-milling), which is a direct solid conversion tech-
nique, can also be used to prepare ASDs, but is still considered as non-
conventional [11].
Despite the fact that solid dispersions are gaining momentum, the
number of polymers that have been used as a carrier for ASDs during
the past 50 years is rather limited [12]. Furthermore, there is currently
a constrained number of 24 solid dispersion formulations marketed
over a period of 30 years, which may be due to large-scale manu-
facturing difficulties and physical stability issues [8,13]. In addition,
this limited market share may also be linked to disadvantages asso-
ciated with currently available polymer carriers. The few carrier op-
tions that formulation specialists have for screening purposes can pose
problems regarding stability and processability. Moreover, no carrier
structure is so versatile that it can serve as a platform for the for-
mulation of a broad range of active pharmaceutical ingredients (APIs)
[6]. Regarding these limitations, poly(2-alkyl-2-oxazoline)s (PAOx) are
thought-provoking as alternative carriers for drug delivery purposes or
in this more specific case for ASDs [14–16]. This polymer class is syn-
thesized by cationic ring opening polymerization (CROP) of 2-sub-
stituted 4,5-dihydrooxazoles, referred to as 2-oxazolines [17]. The
polymerization of 2-oxazolines allows full control over the polymer
molar mass and side-chain composition, enabling the production of
materials with a wide range of solubility properties: from super-
hydrophilic via thermoresponsive to superhydrophobic [18]. The in-
troduction of chain-end as well as side-chain functionalities into the
polymer structure is as well straightforward [19,20]. Hence, a platform
of differently substituted PAOx could be envisioned for the formulation
of a wide variety of APIs with different physicochemical properties.
Based on subtle structural variations, it may be anticipated that dif-
ferent dissolution properties can be obtained. This tunability of hy-
drophilicity can be useful to further optimize formulations regarding
drug release or to produce immediate as well as sustained release for-
mulations [14]. In addition to structural versatility, processability is a
major advantage for this relatively new class of polymers [14,17].
Moreover, PAOx are considered to pose high physical and chemical
stability and are proven to be biocompatible [21,22]. Recent publica-
tions propose the potential of poly(2-ethyl-2-oxazoline) (PEtOx) (i.e. a
PAOx with ethyl side-chains) as ASD carrier, namely Claeys et al. in-
vestigated the potential of PEtOx as a matrix excipient using HME as
manufacturing technology and set forth the possibility of molecularly
dispersing a poorly soluble drug within the polymer, thereby enhancing
the dissolution rate [14]. The research of Fael et al. certified this aspect
using the solvent evaporation method and even stated that PEtOx could
serve as an alternative to polyvinylpyrrolidone (PVP) for improving
oral bioavailability of poorly water-soluble drugs [15]. However, our
research goes beyond merely examining the possibility of preparing
ASDs with PEtOx and elaborating the resulting drug solubility enhan-
cing effects. The overall aim of this study is to investigate the potential
of PEtOx by applying a benchmark approach, which allows comparison
to three well-known, commercially available carriers namely PVP K30,
poly(vinylpyrrolidone-co-vinyl acetate) (PVP-VA) 64 and hydro-
xypropylmethylcellulose (HPMC). For this purpose, we investigate the
formation of ASDs with defined PEtOx, in contrast to previous reported
studies that used technical grade PEtOx (brand-named Aquazol®), with
itraconazole (ITC) and fenofibrate (FFB) as selected BCS class II model
drugs. The four polymers were compared by establishing the super-
saturation maintaining potential and by elaborating their capability as
carrier for ASDs with high drug loadings. Since it is known that dif-
ferent ASD manufacturing techniques will result in different product
properties, ASDs were prepared with a heat-based technique (i.e. HME),
as well as with a solvent-based technique (i.e. spray drying) and a
mechanochemical activation technique (i.e. cryo-milling). For each
manufacturing technique, the formulations with the highest possible
drug loadings were tested with respect to in vitro drug release kinetics.
Since the focus lies on the investigation of the potential of PEtOx to
form a one phase ASD with a poorly soluble model drug, to evaluate the
drug release from these systems and to study the supersaturation
maintaining properties, physical stability studies were not within the
aim of this research and therefore not conducted.
2. Materials and methods
2.1. Materials
ITC and FFB were obtained from Janssen Pharmaceutica N.V.
(Beerse, Belgium) and Hangzhou DayanChem (Hangzhou City, China),
respectively. Defined PEtOx with a molar mass of 50,000 g/mol and a
dispersity of 1.15 and 25,000 g/mol poly(2-methyl-2-oxazoline)
(PMeOx) with a dispersity of 1.34 (measured by Size Exclusion
Chromatography against poly(methyl methacrylate) standards) were
prepared following our recently published improved synthesis protocol
[23]. PVP K30 and PVP-VA 64 were both obtained from BASF®
ChemTrade GmbH (Ludwigshafen, Germany) and HPMC 2910
(5mPa s) was purchased from Colorcon (Dartford, UK).
HCl was purchased from Fisher Scientific U.K. Limited
(Loughborough, UK), NaH2PO4·H2O from Honeywell (Seelze, Germany)
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and Na2HPO4 from Sigma-Aldrich GmbH (Steinheim, Germany).
Biorelevant.com (Croydon, U.K.) provided FaSSIF/FaSSGF/FeSSIF
powder. NaCl and NaOH were supplied by Chemlab N.V. (Zedelgem,
Belgium) and Merck (Darmstadt, Germany), respectively.
Polytetrafluorethylene (PTFE) filters were obtained from VWR
International and dimethylsulfoxide (DMSO) was purchased from
ACROS (Geel, Belgium). Fisher Scientific U.K. Limited (Loughborough,
UK) supplied acetonitrile (ACN). Acetic acid and sodium acetate were
both obtained from VWR Chemicals (Leuven, Belgium).
Dichloromethane (DCM), methanol (MeOH), phosphoros pentoxide and
Na3PO4·12H2O were all acquired from ACROS (Geel, Belgium).
2.2. Solubility and supersaturation experiments
Solubility and supersaturation experiments were carried out in
simple as well as in more advanced (more biorelevant) media. Both
acidic and neutral media were implemented, given the simulation of the
gastro-intestinal tract environment in pharmaceutical performance ex-
periments. HCl 0.1M and a 20mM phosphate buffer were used as
simple acidic and neutral medium respectively. Biorelevant acidic
medium (fasted state simulated gastric fluid - FaSSGF) was obtained by
dissolving FaSSIF/FaSSGF/FeSSIF powder (0.060mg/mL) in 1 L pur-
ified water, containing 2 g of NaCl. The pH of this solution was adjusted
to 1.6 with 1M HCl after magnetic stirring for 2 h. To prepare bior-
elevant neutral medium, consisting of ¼ FaSSGF and ¾ FaSSIF (fasted
state simulated intestinal fluid), the latter component was made by
dissolving 5.26mg/ml NaH2PO4·H2O, 8.23mg/ml NaCl, 0.56mg/ml
NaOH and 2.99mg/ml FaSSIF/FaSSGF/FeSSIF powder in purified
water. After 2 h of magnetic stirring, the pH was subsequently adjusted
to 6.5. In this paper, the term ‘biorelevant neutral medium’ is often
replaced with the term ‘FaSSIF’. However, the reader should keep in
mind that these terms refer to the mixture of FaSSGF and FaSSIF. The
biorelevant media were used for experimental work within 48 h after
the preparation.
2.2.1. Solubility experiments
The thermodynamic solubility of ITC and FFB was determined in
triplicate in 10mL glass test tubes using the shake-flask method for
48 h. An excess of API was added to 5mL aqueous media (both simple
and biorelevant media), either in presence or absence of 0.5% (w/V)
PVP K30, PVP-VA 64, HPMC, PEtOx or PMeOx. After 48 h, samples
were filtered through pre-saturated PTFE filters (0.2 µm) and analysed
as such with HPLC.
2.2.2. Supersaturation experiments
The supersaturation behaviour of ITC and FFB was investigated in
triplicate by using the solvent-shift method, either in absence or pre-
sence of 0.5% (w/V) PVP K30, PVP-VA 64, HPMC, PEtOx or PMeOx
(both in simple and biorelevant media), in order to draw conclusions on
the precipitation inhibition capacity of the different polymers. Based on
the determined equilibrium solubility, 1.0mL stock solutions of API in
DMSO were prepared to obtain a degree of supersaturation (DS) of 20.
From these stock solutions, 200 µL were added to glass beakers, con-
taining 19.80mL media either with or without polymer, which were
continuously stirred throughout the experiment. Samples were taken
after predetermined timepoints (15, 30, 45, 60 and 120min), filtered
through pre-saturated PTFE filters (0.2 µm) and subsequently diluted
threefold with mobile phase for HPLC analysis. Supersaturation factors
(SF) for the time range 15–120min were calculated by using the mean
area under the curve (AUC) values, according to the following equation:
=SF supersaturation in presence of polymer
solubility in presence of polymer
AUC (15 120 min)
AUC (15 120 min)
(1)
Note that (for both solubility and supersaturation experiments)
adsorption of ITC and FFB to PTFE filters (0.2 µm) was investigated
upfront by HPLC analysis of subsequently filtered fractions of a satu-
rated API solution. This led to the conclusion that, for both ITC and FFB,
10mL of a saturated API solution (i.e. in simple acidic medium) are
needed in order to pre-saturate the filters before use.
2.3. High performance liquid chromatography (HPLC)
Quantification of ITC and FFB concentrations was done by HPLC
analysis using a VWR HITACHI Chromaster System (consisting of a
5160 pump, a 5260 autosampler, a 5310 column oven and a 5410 UV
detector), equipped with a Nucleodur C-18 column (150mm, 4.6mm
ID, particle size 5 µm) obtained from Macherey-Nagel (Düren,
Germany). Data acquisition was performed using Chromaster System
Manager Software (version 1.1). An isocratic HPLC-method was de-
veloped for both ITC and FFB. In case of ITC, acceptable retention times
of approximately 4.5 min and hence run times of 7min were obtained
by using a mobile phase consisting of ACN/25mM sodium acetate
buffer (pH 3.50) in a ratio of 75/25 (V/V), a flow rate of 1mL/min and
20 µL injection volume. The detection wavelength was set at 262 nm.
For FFB, the mobile phase consisted of ACN/25mM sodium acetate
buffer (pH 3.50) in an 85/15 (V/V) ratio, resulting in acceptable re-
tention times (ca. 5min) and run times of 7min. As for ITC, a flow rate
of 1mL/min and an injection volume of 20 µL were applied, but with
the detection wavelength set at 290 nm. These methods were validated
for linearity (coefficient of determination R2 > 0.995) and for intra-
and inter-day variability. The limit of detection (LOD) and limit of
quantification (LOQ) were determined based on signal to noise ratios,
resulting in values of 4.8 ng/mL and 16 ng/mL, respectively (i.e. for
ITC) and values of 5.35 ng/mL and 18 ng/mL, respectively (i.e. for FFB).
2.4. ASD manufacturing
2.4.1. Spray drying
Spray dried formulations were prepared with a Büchi mini spray
dryer B-191 (Büchi, Flawil, Switzerland). An accurate amount of API
and polymer (either PVP K30, PVP-VA 64, HPMC or PEtOx) was dis-
solved in a binary solvent mixture of DCM:MeOH (1:1, V:V) in order to
obtain a solid content of 10% w/V. The drying air temperature in the
drying chamber was set at 52 °C, i.e. the average of the boiling points of
DCM and MeOH (39.6 °C and 64.7 °C, respectively) and the drying air
flow rate at 33m3/h. The feed solution flow rate was set at 5mL/min
and the atomization air flow rate at 10 L/min. For FFB-PEtOx for-
mulations, the above-described parameters were adapted in order to
obtain a powder. In this case, pure DCM was used as solvent and the
drying air temperature was set at 35 °C. The feed solution flow rate was
halved and the atomization air flow doubled. Immediately after spray
drying, the collected ASDs were further dried in a vacuum oven for 72 h
at room temperature. Afterwards, the samples were stored at −28 °C in
the presence of phosphorus pentoxide until further analysis (i.e. solid-
state characterization and determination of drug release kinetics).
2.4.2. Hot melt extrusion
Physical mixtures of drug-polymer combinations were prepared
with a mortar and pestle and extruded using a Mini extruder, supplied
by DSM Xplore (Sittard, The Netherlands). The extruder is a fully in-
termeshing recirculating 5 cm3 extruder, consisting out of two co-ro-
tating screws. In case of ITC, the barrel temperature was set at 170 °C,
which is above its melting point (Tm) (i.e. 168 °C). For the FFB for-
mulations with PEtOx, a barrel temperature of 85 °C was applied, based
on the Tm of FFB (i.e. 80 °C). For the FFB-PVP-VA, FFB-PVP and FFB-
HPMC formulations, a barrel temperature of 10 °C above the Tg of the
polymer was applied, being 120 °C, 170 °C and 160 °C, respectively. For
every batch, about 5 g was fed into the extruder via the hopper and
mixed for 5min with a screw speed of 100 rpm. The extrudates were
collected and cooled on aluminum foil and milled for 3min using a
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laboratory cutter mill (Kika, Staufen, Germany).
The milled extrudates were subsequently sieved (through a 355 µm
sieve) and stored at −28 °C in the presence of phosphorus pentoxide
until further analysis (i.e. solid-state characterization and determina-
tion of drug release kinetics).
2.4.3. Cryo-milling
Cryogenic grinding was performed using a CryoMill (Retsch,
Düsseldorf, Germany). Physical mixtures of drug-polymer combinations
were prepared using a mortar and pestle and transferred into stainless
steel grinding jars of 5mL (±200mg physical mixture) with three
10mm stainless steel beads. The samples were cryo-milled by applying
the following conditions: a pre-cooling period of 1min at 5 Hz and a
cryo-milling period of 3 h at 25 Hz (liquid nitrogen: −196 °C). To
prevent overheating, the 3 h interval was evenly spread over six inter-
vals of 30min at 25 Hz, alternated with an oscillation period of 5min at
5 Hz. The resulting powder samples were stored at −28 °C in the pre-
sence of phosphorus pentoxide until further analysis (i.e. solid-state
characterization and determination of drug release kinetics).
2.5. Solid-state characterization
2.5.1. Modulated differential scanning calorimetry (mDSC)
A Q2000 mDSC (TA Instruments, Leatherhead, UK), equipped with
a refrigerated cooling system (RCS90) and a dry nitrogen purge with a
flow rate of 50mL/min, was used. Calibration for temperature, en-
thalpy and heat capacity was carried out using indium and sapphire
standards. The following parameters were applied: a linear heating rate
of 2 °C/min combined with a modulation amplitude of 0.212 °C and a
period of 40 s. Approximately 1–3mg of the sample were accurately
weighed into aluminum DSC pans (TA Instruments, Zellik, Belgium).
For the samples containing ITC, a heating procedure ranging from 0 °C
to 200 °C was applied. For samples with FFB, the heating procedure
ranged from −40 °C to 100 °C (for FFB-PEtOx systems), to 120 °C (for
FFB-PVP-VA systems) and to 170 °C (for FFB-PVP and FFB-HPMC sys-
tems). DSC thermograms were analysed using Universal Analysis soft-
ware (Version 5.5, TA Instruments, Leatherhead, UK).
2.5.2. X-ray powder diffraction (XRPD)
XRPD was performed using an X’Pert PRO diffractometer
(PANalytical, Almelo, the Netherlands) with a Cu tube (Kα
λ=1.5418 Å) and a generator set at 45 kV and 40mA. The measure-
ments were executed at room temperature, in transmission mode using
Kapton® Polyimide Thin-films (PANalytical, Almelo, the Netherlands).
The following experimental settings were selected: continuous scan
mode from 4° to 40° 2θ with 0.0167° step size and 400 s counting time.
The diffractograms were analysed using X’Pert Data Viewer (Version
1.7, PANalytical, Almelo, The Netherlands).
2.6. In vitro drug release kinetics
In vitro drug release kinetics were explored in simple media with an
SR 8 Plus dissolution testing system (Hanson Research, U.S.), thermo-
statically maintained at 37 °C ± 0.5 °C. Dissolution behavior was as-
sessed according to the United States Pharmacopeia (USP) using the
paddle method (USP Apparatus 2) at 75 rpm. The selected solid dis-
persions (equivalent to a 100mg itraconazole or fenofibrate dose) were
added to the vessels, each containing 400mL of simple acidic medium.
Simple acidic medium for dissolution purposes was obtained by adding
0.5% (w/V) polysorbate 80 to a tenfold dilution of 1M HCl with pur-
ified water and adjusted to pH 1. Drug release was monitored in this
medium for 1 h, then a pH shift was performed (with the aim of
reaching a pH value of 6.8) by adding approximately 100mL of an
alkaline solution, consisting of 0.25M Na3PO4·12H2O in purified water.
Drug release in this neutral environment was monitored subsequently
for 4 h. At predetermined time points, 1.5 mL of sample was withdrawn
and centrifuged for 7min at 14,680g with an Eppendorf centrifuge
5424 (Hamburg, Germany). The supernatant was filtered through pre-
saturated PTFE filters (0.2 µm) and subsequently fivefold diluted with
mobile phase for HPLC analysis. All experiments were performed in
triplicate. After each sampling, the volume of the vessel was refilled
with 1.5 mL pure medium. Quantification of drug concentrations was
done with HPLC using the previously developed and validated methods.
2.7. Statistical analysis
Solubility data were statistically analysed with one-way ANOVA
combined with post-hoc t-tests, adjusted with the Bonferroni correction
for multiple testing, in order to conclude whether the resulting solu-
bility values of ITC/FFB in presence of the different polymers sig-
nificantly differ (p < 0.01) from the solubility value of the drug in pure
medium. Data from the supersaturation experiments were statistically
analysed with one-way ANOVA combined with post-hoc t-tests, ad-
justed with the Bonferroni correction for multiple testing in order to
state whether SF in presence of different polymers significantly differ
(p < 0.01) from SF of pure medium. Finally, data obtained from the in
vitro dissolution tests were statistically analysed with one-way ANOVA
(i.e. based on normalized AUC values, p < 0.05).
3. Results and discussion
In order to make a clear statement about the potential of PEtOx as
ASD carrier in comparison to well-known carriers, a systematic ap-
proach is implemented. First, equilibrium solubility values of both
drugs are determined in absence and presence of the different polymers
(Section 3.1), followed by supersaturation experiments (Section 3.2). In
a next step, ASDs are manufactured and for each formulation and each
manufacturing technique the highest possible drug loading that still
results in a one phase amorphous system is established (Section 3.3).
Finally, these highest possible drug loading formulations are evaluated
for their pharmaceutical performance by in vitro dissolution testing
(Section 3.4).
3.1. Solubility experiments
Equilibrium solubility values of ITC and FFB, either in absence or
presence of polymer, are graphically depicted in Fig. 1. As can be seen,
the results of the solubility experiments with ITC clearly demonstrate
higher equilibrium solubility values in acidic medium compared to
neutral medium. This is attributed to protonation since ITC is a weak
base (i.e. with pKa values of 2.2 and 3.1, corresponding to the triazole
and piperazine function, respectively) [9]. Data of the solubility ex-
periments conducted in simple media illustrate that solubility values of
ITC were consistently higher in the presence of a polymer. Moreover, in
some cases, statistically significant increases in solubility values were
observed. For biorelevant media, in contrast, the influence of the
polymers on the solubility was less clear and in most cases the solubility
values slightly decreased when polymers were present. However, these
values did not significantly differ from the values obtained in pure
media. Higher solubility of ITC in simple acidic media compared to
biorelevant acidic media and similar solubility values for simple and
biorelevant neutral media can possibly be attributed to pH effects since
the pH of simple media (pH=1 for acidic simple media, pH=6.8 for
neutral simple media) slightly differ from the pH of biorelevant media
(pH=1.6 for FaSSGF and pH=6.5 for FaSSIF).
The results of the solubility experiments with the non-ionizable FFB
(see Fig. 1C–D) show pH independent values with respect to simple
media. The upward trend in equilibrium solubility values (simple
media < FaSSGF < FaSSIF) can be explained by the presence of so-
lubilizing effects due to micellar solubilization, which is more pro-
nounced in FaSSIF than in FaSSGF. It can be noted that FFB is more
prone to the solubilizing effects of the biorelevant media when
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compared to ITC, which is probably due to the ‘grease ball’ character of
FFB (=hydrophobic) opposed to the ‘brick dust’ property of ITC
(=strong crystal lattice). As for ITC, experiments conducted in simple
media indicate that FFB solubility values were consistently higher in the
presence of a polymer, although not statistically significant. The in-
fluence of the polymers on solubility was less clear in biorelevant
media.
Evaluating the solubility data, it is indeed difficult to distinguish
between the different polymers, let alone to make a statement about the
potential of PEtOx as ASD carrier.
3.2. Supersaturation experiments
Based on the obtained solubility values, supersaturation experi-
ments were carried out starting from a DS of 20, as applied in previous
research [24]. Time-concentration profiles of supersaturation experi-
ments with ITC in biorelevant media are illustrated in Fig. 2 as a re-
presentative example. Note that only the solubility of ITC in pure media
is depicted since these values do not significantly differ from the values
obtained in presence of polymer. However, SF are calculated according
to [Eq. (1)], thereby using AUC values based on solubility values in
presence of polymer. An overview of the SF for the two compounds in
the various media is provided in Table 1. It can be concluded that the
polymers exerted little to no effect to inhibit the precipitation of ITC or
FFB when compared to SF in pure media. The phenomenon of drug
supersaturation in pure media has been reported in literature for ITC.
Bevernage et al. observed supersaturation of ITC in human gastric fluids
without inclusion of precipitation inhibitors, which was ascribed to
charge repulsion. However, the authors state that this repulsion cannot
be invoked as the main determinant for supersaturation stability of
weakly basic compounds and can also not explain the observed effect in
neutral medium, let alone for FFB. The rationale behind this observed
effect thus still remains elusive [24]. It is hypothesized that another
experimental procedure may lead to more pronounced differences be-
tween the different polymers. For example, Tonnis et al. pointed out
that differences can be seen in drug supersaturation depending on
whether the polymer is pre-dissolved in the media or co-dissolved in the
drug solution [25]. Co-dissolved polymers can lead to the formation of
drug-polymer interactions (e.g. pre-formed hydrogen bonds) and hence
better resist the interaction disruption upon addition to the aqueous
medium. The method applied in this research encompasses pre-dis-
solved polymers in the media, possibly inducing weaker drug-polymer
interactions (i.e. minimal H-bonding) and less supersaturation effects,
thereby making it more difficult to observe differences. In conclusion it
can be formulated that even though supersaturation experiments do not
allow to distinguish between the different polymers, they do reveal that
PEtOx is able to maintain supersaturation of ITC and FFB to the same
extent as the commercially available polymers. Due to the similar
outcomes observed for PMeOx and PEtOx and the limited availability of
PMeOx, only PEtOx was withheld for ASD manufacturing.
3.3. ASD manufacturing: Determination of highest possible drug loading
A drug loading screening (most often with 35% drug loading as
starting point) was performed for each formulation and each manu-
facturing process, in order to define the highest possible drug loading
that still results in a single phase amorphous system. Noteworthy, drug
loadings are based on weight and hence refer to the drug weight frac-
tion in the formulation. Given the potential physical stability issues of
ASDs, relatively low drug loadings are utilized in general (ca. 30–35%).
Fig. 1. Average equilibrium solubility values of ITC (in mg/mL) in the absence (in green)/presence of polymers, both in acidic and neutral biorelevant media (A) and
acidic and neutral simple media (B). Average equilibrium solubility values of FFB (in mg/mL) in the absence (in green)/presence polymers, both in acidic and neutral
biorelevant media (C) and acidic and neutral simple media (D). Values with * indicate solubility values that significantly differ from the solubility value in pure
medium (p < 0.01). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Nevertheless, it is of utmost importance to obtain drug loadings as high
as possible, aiming to lower the pill burden and/or reduce the dosage
size to enhance therapeutic compliance of the patient.
3.3.1. Spray drying
Firstly, the same drug loading of ITC was spray dried in combination
with each of the four polymers. Applying a 35% drug loading resulted
in a different phase behavior for the different formulations (see Fig. 3).
Solid-state characterization of the spray dried starting formulations
revealed that drug loadings can be increased further for ITC-35-PEtOx
and ITC-35-HPMC formulations, since mDSC thermograms show a
single Tg indicating a one phase amorphous system. In one phase
amorphous systems, the Tg is most often located between the Tg of the
pure amorphous drug and the one from the polymer. While in Fig. 4, the
drug increasing approach is only described for spray dried ITC-PEtOx
systems, the same principle was applied for all drug-polymer combi-
nations, irrespective of the manufacturing technique used, of which the
starting formulation is characterized by both a single Tg and halo pat-
tern. New formulations with higher drug loadings were prepared, using
consecutive steps of 5%. Since a melting point appears for the ITC-45-
PEtOx formulation, ITC-40-PEtOx is selected as highest possible drug
loading ASD formulation. Importantly, from the melting events in-
dicating crystallinity, it can be noted that the melting points of ITC
slightly differ from the one of the pure drug. It can be argued whether
the melting events correspond to the melting of the most stable ITC
polymorph (i.e. 168 °C), subject to melting point depression, or to the
melting of the metastable itraconazole Form II polymorph (i.e. 155 °C)
[26,27].
As clearly seen in Fig. 3, in contrast, the drug loading had to be
lowered for the ITC-35-PVP-VA formulation because of amorphous-
amorphous phase separation (which in turn can culminate in crystal-
linity) indicated by two Tg’s in the reversing heat flow (RHF) of the
mDSC thermogram, corresponding to a drug-rich and polymer-rich
phase. For the ITC-35-PVP formulation, drug loading also had to be
lowered, given the endothermal peak signaling crystallinity. In addition
to crystallinity, interestingly, the mDSC thermogram (Fig. 3A) of ITC-
35-PVP indicates a Tg at approximately 60 °C and two endothermal
peaks at temperatures 74 °C and 90 °C. These events are attributed to a
chiral nematic mesophase of ITC, as described by Six et al. [26]. This
mesophase, also known as the liquid crystalline phase, is an additional
phase that can be identified between the anisotropic, long-range or-
dered solid state and the isotropic, short-range ordered liquid state.
Since only one phase amorphous systems are being sought in this re-
search, drug loading had to be lowered for the ITC-PVP formulation.
Formulations with lower drug weight fractions were prepared by con-
secutive steps of 5% and solid-state characterization outcomes are de-
picted in Fig. 5, which serves as an example for all drug lowering ap-
proaches applied in this research. Finally, the drug loading screening of
the spray dried formulations resulted in highest drug weight fractions of
20% for ITC-PVP, 30% for ITC-PVP-VA and 40% for both ITC-PEtOx
and ITC-HPMC drug-polymer combinations, as outlined in Table 2.
Interestingly, for spray dried formulations, an equally high drug loading
can be achieved with PEtOx as with HPMC, the polymer which is cur-
rently used for commercialization of ITC (i.e. Sporanox® and Onmel™).
XRPD diffractograms of all spray dried starting formulations show
Fig. 2. Time-concentration profiles of supersaturation experiments with ITC in (A) acidic biorelevant medium and in (B) neutral biorelevant medium. The reference
solubility of pure ITC is found in green. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Average supersaturation factors (SF) ± standard deviation. Values indicated
with * indicate SF that significantly differ from the SF of pure medium
(p < 0.01).
Itraconazole
Acidic medium Neutral medium
Pure medium 18.3 ± 0.3 Pure medium 3.76 ± 0.02
PVP 17.9 ± 0.08 PVP 3.35 ± 0.08
PVPVA 17.5 ± 0.7 PVPVA 3.9 ± 0.4
HPMC 17.0 ± 0.9 HPMC 4.47 ± 0.05*
PEtOx 16.5 ± 1.6 PEtOx 3.8 ± 0.4
PMeOx 17.7 ± 0.5 PMeOx 3.05 ± 0.12*
FaSSGF FaSSGF+FaSSIF
Pure medium 17.1 ± 0.3 Pure medium 17.2 ± 0.3
PVP 15.7 ± 0.3* PVP 17.3 ± 0.2
PVPVA 16.4 ± 0.3 PVPVA 17.1 ± 0.2
HPMC 15.9 ± 0.14* HPMC 18.2 ± 0.13*
PEtOx 16.7 ± 0.2 PEtOx 16.3 ± 0.4
PMeOx 19.4 ± 0.4* PMeOx 17.2 ± 0.12
Fenofibrate
Acidic medium Neutral medium
Pure medium 5.5 ± 0.9 Pure medium 4.4 ± 0.3
PVP 3.6 ± 0.5 PVP 2.6 ± 0.2*
PVPVA 4.9 ± 0.5 PVPVA 2.4 ± 0.2*
HPMC 4.0 ± 0.3 HPMC 2.5 ± 0.2*
PEtOx 3.5 ± 0.3 PEtOx 1.88 ± 0.06*
PMeOx 0.95 ± 0.10 PMeOx 0.646 ± 0.010*
FaSSGF FaSSGF+FaSSIF
Pure medium 4.8 ± 0.2 Pure medium 1.59 ± 0.04
PVP 3.32 ± 0.07* PVP 1.6 ± 0.2
PVPVA 3.21 ± 0.03* PVPVA 1.8 ± 0.2
HPMC 3.57 ± 0.07 HPMC 1.60 ± 0.04
PEtOx 3.28 ± 0.02* PEtOx 1.53 ± 0.09
PMeOx 3.77 ± 0.18* PMeOx 3.8 ± 1.1
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an amorphous halo (see Fig. 3B). The small observable peaks just before
15° are due to Kapton Polyimide Film since XRPD measurements are
conducted in transmission mode. Hence, mDSC was found to be deci-
sive in the drug loading screening of spray dried ITC since no diffraction
peaks could be observed for any formulation, even if mDSC revealed
some crystallinity. The higher sensitivity of mDSC compared to XRPD
can serve as an explanation for this observation. It is thus hypothesized
that too few crystals are present in the sample to be detected with XRPD
or that the length of coherence is reduced. Moreover, amorphous-
amorphous phase separation can only be distinguished from a single
amorphous system with mDSC, because XRPD shows an amorphous
halo in both cases. Despite XRPD shortcomings, it is still indispensable
to implement both mDSC and XRPD as complementary solid-state
analytical techniques to provide a comprehensive characterization of
the prepared ASDs. A recent paper of Dedroog et al. [28] pointed out
that properties of the ASD sample can alter when applying a heating
procedure during mDSC. Even a small amount of heat can incite dis-
solution of the API in the polymer matrix, resulting in mDSC profiles
which do not show crystallinity in contrast with the corresponding
diffractograms containing diffraction peaks. A similar case was also
reported by Bikiaris et al., further highlighting the importance of
combining both techniques [29]. An additional problem associated to
the use of mDSC as stand-alone technique for solid-state characteriza-
tion is the overlap of solvent evaporation with recrystallization or
melting events, which is often the case for drugs with low melting
points (e.g. FFB, Tm=80 °C).
In a next step, the same drug loading screening approach was ap-
plied for FFB. FFB, with a starting drug weight fraction of 35%, was
spray dried in combination with each of the four polymers and resulted
in a drug lowering approach for all formulations due to melting events
on the mDSC thermograms and Bragg peaks in the corresponding dif-
fractograms. As reported in Table 2, lowering the drug loadings resulted
in the determination of the highest possible drug loading for each for-
mulation: 5% for FFB-PVP-VA, 10% for FFB-PEtOx and 20% for FFB-
HPMC systems. The spray dried FFB-5-PVP formulation still showed
Bragg peaks in its diffractogram and therefore the highest possible drug
loading is indicated as “below 5%”. In contrast to spray dried ITC for-
mulations, XRPD was found to be decisive in the determination of the
highest possible drug loading for FFB-PVP and FFB-PVP-VA systems.
For example, mDSC thermograms of FFB-PVP systems indicated the
formation of single Tg amorphous systems as from 25% drug loading, in
contrast with their corresponding diffractograms signaling crystallinity.
As indicated above, overlap of solvent evaporation with the melting
event of FFB can serve as a possible explanation. The other hypothesis,
which implies that due to mobility inducement, FFB dissolves in the
polymer during heating, may also apply here since the melting event
starts at the beginning of the glass transition. It is important to note
that, for spray drying of low Tg FFB-PEtOx systems, process parameters
were altered in order to obtain a powder. Hence, it could be argued to
what extent this resulting drug loading can be compared to those of the
Fig. 3. (A) mDSC thermograms of 35% ITC spray dried formulations with different carriers: PVP (black), PVP-VA (red), HPMC (blue) and PEtOx (pink). The arrows
indicate the positions of the Tgs. The reversing heat flow (RHF) signals are shown as arbitrary units. Noteworthy, the thermogram of the spray dried 35% ITC-PVP
system indicates the formation of a chiral nematic mesophase. (B) Corresponding XRPD diffractograms and the diffractogram of pure ITC (green) as comparison. The
intensities are shown as arbitrary units. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. (A) mDSC thermograms of spray dried ITC-PEtOx systems, increasing the drug loading from 35% to 45% by intermediate steps of 5%. The arrows indicate the
positions of the Tgs. The RHF signals are shown as arbitrary units. (B) Corresponding XRPD diffractograms and the diffractogram of pure ITC (green) as comparison.
The intensities are shown as arbitrary units. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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other formulations. The influence of process parameters on the final
product properties was, however, not within the aims of this study.
Although the outcome of the drug loading screening is strongly API
dependent, it does provide a first proof of the potential of PEtOx for
drug formulation purposes. The ease and the speed with which PEtOx
dissolves in various solvents offers an additional argument in favor of
this polymer.
3.3.2. Hot melt extrusion
A 35% drug loading of ITC was extruded with each of the four
polymers but, in contrast to spray drying, resulted in the same phase
behavior for all drug-polymer combinations (see Fig. 6). Thermograms
of all hot melt extruded starting formulations indicate that one phase
amorphous systems were obtained, hence drug loadings were increased.
As a result, drug loadings of 35% were obtained for ITC-HPMC and ITC-
PVP formulations, 40% for ITC-PEtOx and a value of 50% was reached
for ITC-PVP-VA. Noteworthy, crystallinity was induced in ITC-40-PEtOx
and ITC-50-PVP-VA systems when the extrudate milling time was in-
creased from 1min to 3min, in order to further reduce the particle size
(i.e.<355 µm) with a view to in vitro dissolution experiments. There-
fore, ITC-35-PEtOx and ITC-45-PVP-VA formulations were manu-
factured and subsequently tested for milling-induced crystallinity.
These formulations turned out to be stable and were therefore selected
as highest possible drug loading (see Table 2). Evidence on the
usefulness of PEtOx as ASD carrier is thus fortified. Moreover, PEtOx
can overcome an important limitation of HME thereby entailing the
possibility of formulating thermolabile drugs with a low melting point
due to its relatively low Tg (i.e. 60 °C) in comparison to the Tg of the
commercially available polymers (i.e. 147 °C for HPMC, 161 °C for PVP
and 110 °C for PVP-VA).
As for spray dried ITC formulations, mDSC was found to be decisive
in the drug loading screening since all diffractograms show an amor-
phous halo, irrespective of the drug loading or polymer used. The sharp
peak in the diffractogram of hot melt extruded ITC-35-HPMC originates
from a crystalline impurity present in the polymer.
Regarding HME of FFB, solid state-characterization of the 35% drug
weight fraction systems affirmed that drug loadings had to be lowered.
The final drug loadings are represented in Table 2. For hot melt ex-
truded FFB-PVP and FFB-PVP-VA systems, XRPD was found to be de-
cisive in the determination of the highest possible drug loading. In this
respect, the hypotheses described for spray dried FFB-PVP and FFB-
PVP-VA systems may also apply here.
3.3.3. Cryo-milling
A 35% drug loading of ITC was cryo-milled in combination with
each of the four polymers and led to the same phase behavior for all
formulations. Thermograms of the cryo-milled starting formulations
point out that drug loadings can be increased further (Fig. 7a). For the
Fig. 5. (A) mDSC thermograms of spray dried ITC-PVP systems, lowering the drug loading from 35% to 20% by intermediate steps of 5%. The arrows indicate the
positions of the Tgs. The RHF signals are shown as arbitrary units. (B) Corresponding XRPD diffractograms and the diffractogram of pure ITC (green) as comparison.
The intensities are shown as arbitrary units. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
Table 2
Overview of the highest possible weight fractions of ITC and FFB, for each formulation and each manufacturing process, that still result in one phase amorphous
systems. The factors that determined these drug loadings are indicated as well. *Indicates formulation with altered process parameters.
Itraconazole
Spray drying Hot melt extrusion Cryo-milling
Drug loading (%) Determining factor Drug loading (%) Determining factor Drug loading (%) Determining factor
PVP K30 20 Chiral nematic mesophase 35 Phase separation 50 Crystallinity
PVP-VA 64 30 Phase separation 45 Milling induced crystallinity 45 Phase separation
PEtOx 40 Crystallinity 35 Milling induced crystallinity 40 Crystallinity
HPMC 40 Crystallinity 35 Crystallinity 45 Crystallinity
Fenofibrate
Spray drying Hot melt extrusion Cryo-milling
Drug loading (%) Determining factor Drug loading (%) Determining factor Drug loading (%) Determining factor
PVP K30 <5 Crystallinity 20 Crystallinity 10 Crystallinity
PVP-VA 64 5 Crystallinity 30 Crystallinity 10 Crystallinity
PEtOx 10* Crystallinity 30 Crystallinity 5 Crystallinity
HPMC 20 Crystallinity 15 Crystallinity < 5 Crystallinity
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cryo-milled ITC-PEtOx formulations, the screening resulted in a max-
imum drug weight fraction of 40% and for the cryo-milled ITC-HPMC
and ITC-PVP-VA formulations, a drug loading up to 45% was reached.
Even 50% drug weight fraction was obtained for the ITC-PVP for-
mulation, as shown in Table 2. Fascinatingly, for ITC, the highest drug
loading for each of the formulations can reproducibly be obtained with
cryo-milling, which is still considered as non-conventional nowadays.
However, the manufacturing of larger quantities (e.g. for in vitro dis-
solution purposes) is time-consuming. In general, Table 2 clarifies that,
next to the drug-polymer combination, the applied manufacturing
technique is a critical factor for reaching high drug loadings. This is in
alignment with some recent findings in literature, which emphasize the
importance of the manufacturing technique used [28].
For cryo-milling of FFB-polymer combinations, a starting point of
15% drug loading was applied. The ASD manufacturing and solid-state
characterization interplay resulted in determination of highest possible
drug loadings, as depicted in Table 2.
3.3.4. Experimental vs theoretical Tg values
For all ITC formulations with 35% drug loading, experimental Tg
values were compared to theoretical Tg values. The latter were calcu-
lated using the following Gordon-Taylor equation [Eq. (2)]:
= ++T w T K w Tw K wgmix 1 g1 2 g21 2 (2)
where w represents the weight fraction, Tg the glass transition tem-
perature (absolute T), subscripts 1 and 2 indicate the amorphous
compounds with the lowest and highest Tg, respectively and K≅ 1 Tg12 Tg2
where represents the density of the amorphous compound.
This equation only applies to ideal mixtures, implying that the
strength of drug-drug and polymer-polymer interactions are of the same
order than that of drug-polymer interactions. Table 3 suggests that the
theoretical values, obtained with Eq. (2), serve as a good prediction for
the corresponding experimental values. Although the ITC-HPMC system
interacts via H-bonds, theoretical Tg values are higher than their ex-
perimental counterpart, suggesting stronger drug-drug and/or polymer-
polymer interactions compared to the drug-polymer interactions.
3.3.5. Tg widths
For all 35% ITC HME and cryo-milled formulations, mDSC ther-
mograms indicate the formation of a one phase amorphous system.
Although a single Tg is detected, it can be interesting at this point to
investigate the Tg widths and the AUC of the derivative of the reversing
heat flow (AUC Der. RHF). Indeed, the broader the Tg, the more het-
erogeneous the solid dispersion is and consequently the sooner phase
separation and thus crystallization may occur. Tg widths and AUC va-
lues are reported for 35% ITC hot melt extruded and cryo-milled for-
mulations and theoretical AUC Der. RHF values and theoretical Tg
widths for the formulations were calculated from the values of the pure
components assuming simple additivity (see Table 4). The results
Fig. 6. (A) mDSC thermograms of 35% ITC hot melt extruded formulations with different carriers: PVP (black), PVP-VA (red), HPMC (blue) and PEtOx (pink). The
arrows indicate the positions of the Tgs. The RHF signals are shown as arbitrary units. (B) Corresponding XRPD diffractograms and the diffractogram of pure ITC
(green) as comparison. The intensities are shown as arbitrary units. The sharp peak in the diffractogram of the ASD with HPMC (blue) originates from a crystalline
impurity present in the polymer. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 7. (A) mDSC thermograms of 35% ITC cryo-milled formulations with different carriers: PVP (black), PVP-VA (red), HPMC (blue) and PEtOx (pink). The arrows
indicate the positions of the Tgs. The RHF signals are shown as arbitrary units. (B) Corresponding XRPD diffractograms and the diffractogram of ITC (green) as
comparison. The intensities are shown as arbitrary units. The sharp peak in the diffractogram of the ASD with HPMC (blue) originates from a crystalline impurity
present in the polymer. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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indicate that the experimental Tg width and corresponding AUC Der.
RHF of the ITC-35-PVP hot melt extruded solid dispersion can be well
predicted theoretically. For the other formulations, theoretical Tg
widths and AUC Der. RHF are systematically lower than their corre-
sponding experimental values, which implies that more heterogeneity is
present in the system than would be expected for an ideal mixture.
3.4. In vitro drug release kinetics
The formulations with the highest possible drug weight fractions
(see Table 2) were selected for pharmaceutical performance test pur-
poses. This is an important criterion to distinguish between the different
formulations and manufacturing processes and hence, to give an answer
to the key question of this research. For ITC, in vitro dissolution was
tested for all highest possible drug loading formulations (i.e. spray
dried, hot melt extruded and cryo-milled formulations) and the re-
sulting time-concentration profiles are shown in Fig. 8(A–C). In con-
trast, for FFB, pharmaceutical performance was only tested for the
highest possible drug loading formulations prepared with HME, due to
lack of polymer material for the spray dried and cryo-milled formula-
tions given the low drug loadings. The time-concentration profiles of
the in vitro dissolution experiment with FFB are depicted in Fig. 8D. For
each formulation, the corresponding drug loading is indicated. Note-
worthy, after 60min, the dissolution medium was subject to a pH shift,
which explains the rapid precipitation of the weak base ITC from this
timepoint on. Solubility values in both acidic and neutral medium are
also represented.
The resulting time-concentration profiles, represented in Fig. 8,
were statistically analysed with one-way ANOVA based on normalized
AUC values before (5–60min) and after (70–300min) the pH shift. The
AUC values were normalized for the polymer content in order to era-
dicate the effect of different polymer quantities. Indeed, it is known that
relative polymer quantities play a role in the release kinetics of the solid
dispersions (i.e. a higher polymer weight fraction in the formulation
will often result in a better release of the drug) [30]. In a first step,
differences between the different formulations, and hence polymers as
such, are analysed per manufacturing technique. Secondly, the focus
lies on the differences between the manufacturing techniques per for-
mulation. Mean normalized AUC values and the corresponding stan-
dard deviations are reported in Table 5.
For ITC spray dried formulations, ANOVA based on normalized AUC
(5–60min) revealed significant differences between the different for-
mulations. It is observed that the formulation with PEtOx shows the
highest normalized AUC value for the first hour of the dissolution ex-
periment. ANOVA based on normalized AUC (70–300min) also shows a
significant difference between the different formulations and further
demonstrate that the formulation with PEtOx underwent a high driving
force for precipitation, resulting in the lowest normalized AUC value for
the timeframe after the pH shift. For ITC HME formulations, the
ANOVA based on normalized AUC (5–60min) also illustrates the
highest normalized AUC values for the ITC-PEtOx formulation, however
not significantly. In addition, no significant differences were observed
between the formulations for the 70–300min timeframe. For ITC cryo-
milled formulations, the ANOVA based on normalized AUC (5–60min)
revealed significant differences between the different formulations.
However, the highest normalized AUC values were obtained for the
formulations with PVP-VA. ANOVA for the 70–300min period also
shows a significant difference between the different formulations and
reveals that the precipitation driving force for ITC-PVP-VA is less pro-
nounced. Noteworthy, for all manufacturing techniques, formulations
with HPMC obtained the highest normalized AUC values for the time-
frame after the pH shift. Despite the fact that the polymers had a limited
effect on the solubility and supersaturation in the above-described ex-
periments, the dissolution of ITC from the ASD was significantly im-
proved as compared to the original ITC material. Overall, it can be
concluded that PEtOx is able to ensure high drug release, irrespective of
the manufacturing technique used.
When focusing on the differences between the manufacturing
techniques for each formulation with ITC, ANOVA based on normalized
AUC (5–60min) values encompasses p-values less than 0.05 and hence
demonstrates significant differences between the different ASD manu-
facturing techniques. It can be concluded that the highest normalized
AUC values are obtained for all formulations prepared with hot melt
extrusion and thus that this manufacturing technique gives rise to the
best in vitro pharmaceutical performance. For ITC-HPMC and ITC-
PEtOx, the ASD preparation methods can be ordered based on phar-
maceutical performance: HME > spray drying > cryo-milling. In
contrast, for ITC-PVP and ITC-PVP-VA the ranking based on pharma-
ceutical performance is as follows: HME > cryo-milling > spray
drying. ANOVA based on normalized AUC (70–300min) only demon-
strates significant differences for the formulations with PVP and PEtOx
and indicates that the highest normalized AUC values are obtained for
this timeframe when cryo-milling was used as manufacturing tech-
nique.
Table 3
Theoretical Tg values, calculated with the Gordon-Taylor equation, and ex-
perimental Tg values for 35% ITC spray dried, hot melt extruded and cryo-
milled formulations. Formulations indicated with * were not one phase amor-
phous systems.
Itraconazole
Theoretical Tg values (°C) Experimental Tg values (°C) - HME
ITC-35-PEtOx 60.0 ITC-35-PEtOx (HME) 58.3
ITC-35-HPMC 112.9 ITC-35-HPMC (HME) 77.3
ITC-35-PVP-VA 92.3 ITC-35-PVP-VA (HME) 94.1
ITC-35-PVP 123.5 ITC-35-PVP (HME) 120.8
Experimental Tg values (°C) - SD Experimental Tg values (°C) - CM
ITC-35-PEtOx (SD) 63.5 ITC-35-PEtOx (CM) 63.8
ITC-35-HPMC (SD) 97.5 ITC-35-HPMC (CM) 77.4
ITC-35-PVP-VA (SD) * 58.1/101.5 ITC-35-PVP-VA (CM) 86.2
ITC-35-PVP (SD) * 55.0/131.1 ITC-35-PVP (CM) 112.9
Table 4
Experimental Tg values, the corresponding Tg widths and areas under curve of
the derivative of the reversing heat flow (AUC Der. RHF) for 35% ITC hot melt
extruded formulations (upper values), for 35% ITC cryo-milled formulations
(lower values) and for the pure components. The last column represents theo-
retical AUC Der. RHF values and theoretical Tg widths for the formulations,
calculated from the values of the pure components.
Itraconazole
Formulation Tg
values
(°C)
Tg
width
(°C)
AUC Der.
RHF
(W *min/
(g * °C))
Theor. AUC
Der. RHF
(W *min/
(g * °C))
Theor. Tg
width
(°C)
ITC-35-PVP 120.8 11.0 0.0032 0.0031 10.9
112.9 14.4 0.0049
ITC-35-PVP-VA 94.1 8.8 0.0056 0.0029 6.4
86.2 7.6 0.0038
ITC-35-HPMC 77.3 14.7 0.0024 0.0020 8.9
77.4 13.6 0.0037
ITC-35-PEtOx 58.3 12.1 0.0055 0.0042 8.8
63.8 13.3 0.0069
Pure component Tg
values
(°C)
Tg
width
(°C)
AUC Der.
RHF
(W *min/
(g * °C))
ITC 60.1 4.9 0.0038
PVP 169.1 14.2 0.0027
PVP-VA 108.5 7.2 0.0025
HPMC 147.3 11.1 0.0011
PEtOx 63.2 11.0 0.0044
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For FFB, pharmaceutical performance was only tested for the
highest possible drug loading formulations prepared with HME and
hence statements about differences between the manufacturing tech-
niques cannot be made. As reported in Table 5, ANOVA based on
normalized AUC values, for both timeframes, revealed that the FFB-PVP
formulation performed significantly better than the other formulations.
In general, with respect to PEtOx, these data highlight its potential
for drug delivery purposes. Although in some cases highest mean nor-
malized AUC values are obtained when PEtOx was used as carrier, its
overall performance is comparable to the well-known, commercially
available carriers.
Furthermore, it can be noted that the mean normalized AUC values
for the timeframe after the pH shift are much higher for FFB formula-
tions, compared to ITC formulations. This can be explained by the non-
ionizable character of FFB compared to the weak base ITC, that pre-
cipitated due to the increase in pH.
Nevertheless, the reader should keep in mind that statistically sig-
nificant differences from in vitro experiments do not necessarily imply
relevance in vivo. In addition, caution is required when generalizing the
data, since statistical power is limited due to small sample sizes (n=3).
Since physical stability tests were not within the aim of this study,
they form an interesting topic and necessity for future research, given
the relatively low Tg of PEtOx. Together with investigation of possible
drug-polymer interactions (i.e. possible van der Waals interactions be-
tween PEtOx and ITC/FFB), a more comprehensive outline of the po-
tential of PEtOx can be achieved.
4. Conclusions
In this study, the potential of PEtOx as ASD carrier was investigated
by means of a benchmark approach with HPMC, PVP K30 and PVP-VA
Fig. 8. Drug release profiles of (A) spray dried ITC formulations, (B) hot melt extruded ITC formulations, (C) cryo-milled ITC formulations, (D) hot melt extruded FFB
formulations. For each formulation, the corresponding drug loading is indicated. Solubility values of ITC (A–C) and FFB (D) both in acidic (green) and neutral
medium (dark blue) are also represented. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 5
Mean normalized AUC values ± standard deviation, resulting from the in vitro
dissolution experiments of the different ITC and FFB formulations prepared
with hot melt extrusion (HME), spray drying (SD) and cryo-milling (CM), before
(5–60min) (i.e. upper values) and after (70–300min) (i.e. lower values) the pH
shift. P-values of one-way ANOVA analyses are also reported.
Itraconazole
Formulation HME SD CM ANOVA
ITC-PVP 12.4 ± 0.7 4.4 ± 0.3 5.4 ± 0.4 p= 3E−06
1.7 ± 0.3 3.1 ± 0.8 3.1 ± 0.3 p= 0.03
ITC-PVP-VA 12 ± 2 4.5 ± 0.4 7.1 ± 0.2 p= 0.002
3.1 ± 0.9 3.51 ± 0.19 4.6 ± 1.1 p= 0.15
ITC-HPMC 12.4 ± 0.4 6.0 ± 0.6 5.4 ± 0.2 p= 1.8E−06
10 ± 9 4.58 ± 0.17 6.5 ± 0.5 p= 0.5
ITC-PEtOx 14.9 ± 0.17 7.3 ± 0.8 4.7 ± 0.2 p= 8E−07
1.9 ± 0.2 2.0 ± 0.5 3.16 ± 0.12 p=0.003
ANOVA p=0.07 p=0.0007 p=0.00004
p=0.2 p= 0.001 p=0.0006
Fenofibrate
Formulation HME
FFB-PVP 10.3 ± 0.6
17.0 ± 0.4
FFB-PVP-VA 6.7 ± 0.2
10.7 ± 0.4
FFB-HPMC 6.2 ± 1.1
13.4 ± 1.0
FFB-PEtOx 6.3 ± 0.6
11.4 ± 0.6
ANOVA p=0.0002
p=1.1E-05
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64. For this purpose, ITC and FFB were selected as BCS class II model
drugs. The four polymers were able to increase equilibrium solubility
values of both ITC and FFB in simple media and showed a comparable
precipitation inhibition capacity in the supersaturation experiments. In
order to thoroughly elaborate their capability as carrier for ASDs, three
manufacturing techniques were implemented (i.e. spray drying, hot
melt extrusion and cryo-milling) in order to cover all three manu-
facturing categories. For each formulation and each manufacturing
technique, a drug loading screening was performed in order to de-
termine the highest possible drug loading that still results in a one
phase amorphous system. This screening led to the conclusion that
ASDs with acceptable drug loadings can be manufactured with PEtOx as
carrier, irrespective of the manufacturing technique used, and thus
provides proof of the potential of PEtOx for drug formulation purposes.
Although in most cases similar results were obtained for the four
polymers, PEtOx offers some additional benefits. The ease and speed
with which PEtOx dissolves in various solvents serves as a time-saving
advantage within the spray drying process. Moreover, the process
temperature during HME can be markedly lowered due its relatively
low Tg, thereby entailing the possibility of formulating thermolabile
drugs. Finally, pharmaceutical performance of the different formula-
tions was tested and revealed that PEtOx can ensure high drug release,
irrespective of the manufacturing technique used. When focusing on the
distinct manufacturing techniques, it can be concluded that HME gives
rise to the best in vitro pharmaceutical performance. Overall, the hereby
reported data substantiate the potential of PEtOx as ASD carrier.
Despite the promising data collected for PEtOx, its widespread use as a
carrier for ASDs is limited by the lack of regulatory approval. Today,
FDA approval for PEtOx is still limited to its use as an adhesive in food
packaging. However, the recent commercial availability of high quality
PEtOx and the current involvement of a PEtOx derivative in clinical
trials predict an exciting future for this polymer in the biomedical
arena.
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